EMA Authorised: Conexxence (denosumab) — Fresenius Kabi Deutschland GmbH

View source ↗

Summary

EMA authorised Conexxence, a denosumab product from Fresenius Kabi Deutschland GmbH, for osteoporosis including postmenopausal osteoporosis. The product is indi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• CONEXXENCE (DENOSUMAB)

Snippet

Status: Authorised. Therapeutic area: Osteoporosis;Osteoporosis, Postmenopausal;Bone Resorption. MAH: Fresenius Kabi Deutschland GmbH. Decision date: 26/02/2026